ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Driving Clinical Trials Forward: The Benefits of Establishing a Strategic Partnership for Flow Cytometry
A thought leadership article authored by multiple contributors from ICON’s R&D department, which focuses on the future of Flow Cytometry as a sophisticated technology.
The life sciences industry in Ireland
Skilled workforce and high-calibre research help Ireland compete internationally in Life sciences industry
A Special Report on Liver Disease: The Phantom Menace
ICON's Martin Benson provides expert commentary on liver disease in this December 2019 DDN News article.
The Evolving Role of the Patient in Clinical Trials
A ‘review of the year’ thought leadership article, authored by Gretchen Goller, discussing the changing role of the patient throughout 2019.
Using Historical Controls for Rare Disease Trials: Challenges and Opportunities
The use of historical controls in rare disease trials, using existing medical history information on a group of similar patients
Transforming Clinical Trials with Digital Tech, and what that means for the Patient
A thought leadership article exploring the evolving role of technology in the clinical trials arena and the importance prioritising the integration and interrelation of technology in 2020.
The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI
An article featuring commentary by Andrew Garrett, discussing the importance of navigating through the hype surrounding AI and the ways in which the Pharma industry can manage expectations.
Innovation in Oncology Drug Development
This Journal of Oncology article highlights recent, innovative changes that are occurring in oncology clinical trial development.
Intricacies of Precision Medicine for Biotechs
Andrew Garrett discusses challenges such as patient recruitment for biotechs developing therapies for targeted populations with rare diseases.
Navigating an Ever Evolving Regulatory and Pharmacovigilance Landscape
Chuhua Wu outlines the variations in the structures, processes and outcomes of pharmacovigilance status among Asian countries.